Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck: Q2 Earnings Snapshot

07/29/2021 | 07:00am EDT

KENILWORTH, N.J. (AP) _ Merck & Co. (MRK) on Thursday reported second-quarter net income of $1.55 billion.

On a per-share basis, the Kenilworth, New Jersey-based company said it had profit of 61 cents. Earnings, adjusted for one-time gains and costs, were $1.31 per share.

The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of $1.30 per share.

The pharmaceutical company posted revenue of $11.4 billion in the period.

Merck expects full-year earnings in the range of $5.47 to $5.57 per share, with revenue in the range of $46.4 billion to $47.4 billion.

Merck shares have fallen 4% since the beginning of the year, while the S&P's 500 index has increased 17%. The stock has fallen roughly 2% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRK at https://www.zacks.com/ap/MRK

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about MERCK & CO., INC.
09/27MERCK : Said to Buy Acceleron Pharma in Rare Diseases Boost
MT
09/27MERCK : Announces KEYTRUDA« (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) ..
BU
09/27MERCK : Says Keytruda Met Primary Endpoint of Overall Survival in Patients With Liver Canc..
MT
09/27MERCK : LYNPARZA (olaparib) in combination with abiraterone significantly delayed disease ..
AQ
09/27MERCK : LYNPARZA (olaparib) in Combination With Abiraterone Significantly Delayed Disease ..
AQ
09/27Merck Says Keytruda Liver Cancer Study Meets Objective
DJ
09/24Health Care Stocks Retreat Friday
MT
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09/24Health Care Stocks Slip Pre-Bell Friday
MT
09/24MERCK : LYNPARZA« (olaparib) in Combination With Abiraterone Significantly Delayed Disease..
BU
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 46 881 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 16,0x
Yield 2021 3,53%
Capitalization 186 B 186 B -
EV / Sales 2021 4,29x
EV / Sales 2022 3,88x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,36 $
Average target price 93,42 $
Spread / Average Target 27,3%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.32%185 702
JOHNSON & JOHNSON3.68%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.19.37%244 283
NOVO NORDISK A/S48.08%227 557
ELI LILLY AND COMPANY34.09%205 250